Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CSL Biotherapies, Inc.
CSL Biotherapies Contracts with U.S. Department of Health and Human Services HHS to Provide Novel a H1N1 Influenza Vaccine Antigen
June 17th, 2009
CSL Biotherapies, Inc. announced that it has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form to support HHS’ pandemic influenza preparedness efforts. The initial order under contract will be for an amount of at least $180 million. CSL Biotherapies anticipates initial delivery of the antigen by September, subject to regulatory approval. The new vaccine antigen will be tested in clinical trials funded by HHS. CSL Biotherapies has also negotiated an option to supply HHS with Novel A (H1N1) antigen filling and finishing services at the company’s manufacturing plants in Kankakee,...
Source: Vaccine Weekly (2009-06-17)
|
